Edition:
United Kingdom

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

17.67USD
17 Jan 2018
Change (% chg)

$-0.08 (-0.42%)
Prev Close
$17.75
Open
$17.80
Day's High
$17.85
Day's Low
$17.55
Volume
60,616
Avg. Vol
80,674
52-wk High
$29.00
52-wk Low
$13.95

Chart for

About

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an... (more)

Overall

Beta: 0.96
Market Cap(Mil.): $705.13
Shares Outstanding(Mil.): 27.76
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Paratek Announces $50.0 Mln Public Offering Of Common Stock

* PARATEK PHARMACEUTICALS INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS SHARES OF COMMON STOCK Source text for Eikon: Further company coverage:

17 Jan 2018

BRIEF-Paratek Provides Update On Pipeline Progress

* PARATEK PHARMACEUTICALS - HAS EARNED A $5 MILLION MILESTONE PAYMENT FROM ALLERGAN FOR DEVELOPMENT OF SEYSARA Source text for Eikon: Further company coverage:

03 Jan 2018

BRIEF-Paratek Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Mln

* PARATEK PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250 MILLION - SEC FILING‍​ Source text (http://bit.ly/2BqNSiB) Further company coverage:

01 Dec 2017

BRIEF-Paratek Pharmaceuticals Q3 loss per share $0.77

* Paratek Pharmaceuticals reports third quarter 2017 financial results, remains on track to complete NDA submissions in first quarter of 2018

08 Nov 2017

BRIEF-Paratek Pharmaceuticals to report Q3 results on Nov 8

* Paratek Pharmaceuticals to report third quarter 2017 financial results and provide update on clinical progress on November 8, 2017 Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline

* Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline in patients with difficult to treat comorbid conditions

06 Oct 2017

BRIEF-Paratek Pharma antibiotic granted additional qualified infectious disease product designation by FDA​

* Paratek Pharmaceuticals Inc - its antibiotic omadacycline has been granted additional qualified infectious disease product designation by U.S. FDA​ Source text for Eikon: Further company coverage:

21 Sep 2017

BRIEF-Paratek Pharmaceuticals Inc Q2 loss per share $0.66

* Paratek Pharmaceuticals, Inc. Reports second quarter 2017 financial results and provides clinical update

02 Aug 2017

BRIEF-Paratek Pharmaceuticals Q2 loss per share $0.66

* Q2 earnings per share view $-0.96 -- Thomson Reuters I/B/E/S Source text for Eikon: (http://bit.ly/2f7JhMk) Further company coverage:

02 Aug 2017

Earnings vs. Estimates